TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34112729

Group type: EXPERIMENTAL
Intervention: Raghu scale for pulmonary fibrosis (R-Scale-PF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: King's Brief Interstitial Lung Disease questionnaire (K-BILD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L)
Number of subjects: 100
Study: 34112873

Group type: EXPERIMENTAL
Intervention: Prosthesis doffing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testing time
Number of subjects: 24
Study: 34112948

Group type: EXPERIMENTAL
Intervention: CEA kinetics based on >0.05 threshold
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: cfDNA, ctDNA, and CA19-9
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Circulating scoring system (CSS) combining CEA kinetics, baseline CA19-9, and cfDNA
Number of subjects: 192
Study: 34113254

Group type: EXPERIMENTAL
Intervention: Qingre Huoxue treatment (QRHXD/QRHXEP)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Methotrexate plus hydroxychloroquine
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Both QRHXD/QRHXEP and Methotrexate plus hydroxychloroquine
Number of subjects: 468
Study: 34113318

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 2792
Study: 34113381

Group type: EXPERIMENTAL
Intervention: Readymade plastic stent with apically repositioned flap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional apically repositioned flap with papillary sparing incisions
Number of subjects: 20
Study: 34113569

Group type: EXPERIMENTAL
Intervention: Bispecific CD19/22 CAR T cells
Number of subjects: 32
Study: 34113571

Group type: EXPERIMENTAL
Intervention: Laterally extended endopelvic resection (LEER)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chemo or targeted therapy alone
Number of subjects: 59
Study: 34113981

Group type: EXPERIMENTAL
Intervention: Total vitamin D intake (highest quartile, median: 1439 IU/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D intake (800-1000 IU/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D intake (>1000 IU/d)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Dietary vitamin D
Number of subjects: 263
Study: 34114913

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 24
Study: 34114954

Group type: EXPERIMENTAL
Intervention: Digital health intervention (tailored Family Gene Toolkit)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison website (control)
Number of subjects: 104
Study: 34115014

Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 20
Study: 34115136

Group type: EXPERIMENTAL
Intervention: Gene therapy for SCD with nonmyeloablative conditioning and related haploidentical donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy for SCD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Busulfan treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing NIH-sponsored trials
Number of subjects: 0
Study: 34115257

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram combined with platelet counts
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 245
Study: 34115385

Group type: EXPERIMENTAL
Intervention: Asciminib (40 mg)
Number of subjects: 0
Study: 34115419

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measure of Ataxia (70-item, scored on a 0-4 Likert scale)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measure of Ataxia
Number of subjects: 147
Study: 34115607

Group type: EXPERIMENTAL
Intervention: Wearable sensors and smartphone apps (Fitbit, Social Rhythms, Roadmap 2.0) for monitoring health and well-being
Number of subjects: 2158

Group type: EXPERIMENTAL
Intervention: Surveys administered through the Roadmap 2.0 app
Number of subjects: 2158

Group type: EXPERIMENTAL
Intervention: Wearable sensor data and biospecimen collection
Number of subjects: 2158
Study: 34115650

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine (DTG/3TC)
Number of subjects: 131
Study: 34115805

Group type: EXPERIMENTAL
Intervention: Sickle-trait hemoglobin
Number of subjects: 0
Study: 34115946

Group type: EXPERIMENTAL
Intervention: Glycemic variability (GV)
Number of subjects: 0
Study: 34116051

Group type: EXPERIMENTAL
Intervention: Slow eaters consuming rice cake meal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Slow eaters consuming white rice meal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Slow eaters
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fast eaters
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 34116134

Group type: EXPERIMENTAL
Intervention: 3D whole-brain stack-of-spirals FISP MRF sequence at 0.55 T
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Measurement precision calculated from 100 simulated pseudo-replicas of in vivo data
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Within-session measurement repeatability evaluation
Number of subjects: 19
Study: 34116329

Group type: EXPERIMENTAL
Intervention: ICS (Inhaled Corticosteroids)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: LABA + ICS (Long-Acting Beta-Agonists + Inhaled Corticosteroids)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: LABA + LAMA (Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: LABA + LAMA + ICS (Triple therapy)
Number of subjects: 846

Group type: COMPARATOR
Intervention: No medication (never used ICS, LABA + ICS, LABA + LAMA, or triple therapy)
Number of subjects: 846
Study: 34116533

Group type: EXPERIMENTAL
Intervention: Capecitabine or 5-fluorouracil in combination with oxaliplatin or irinotecan
Number of subjects: 68
Study: 34116642

Group type: EXPERIMENTAL
Intervention: Infrared thermography (IT) measuring skin temperature difference (Td) after thoracic paravertebral block (TPVB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Infrared thermography (IT) measuring skin temperature difference (Td)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pinprick test
Number of subjects: 61
Study: 34116645

Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic therapies
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapies
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapies
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Insulin therapies
Number of subjects: 552

Group type: COMPARATOR
Intervention: HbA1c treatment target not achieved (HbA1c ≥ 7.0%)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Blood pressure treatment target not achieved (BP ≥ 140/90 mmHg)
Number of subjects: 552

Group type: COMPARATOR
Intervention: LDL-cholesterol treatment target not achieved (LDL-cholesterol ≥ 2.6 mmol/L)
Number of subjects: 552
Study: 34116675

Group type: EXPERIMENTAL
Intervention: Low-energy diets (LED)
Number of subjects: 71
Study: 34116699

Group type: EXPERIMENTAL
Intervention: Integration of depression services into NCD care
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Availability of antidepressants at the clinic
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Training of NCD staff on depression assessment and care
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Engaging hospital leaders to create an integration policy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reorganizing clinic flow
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ongoing trainings and supervisions
Number of subjects: 19
Study: 34116727

Group type: EXPERIMENTAL
Intervention: ABLE intervention (8-week home-based occupational therapy program)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ABLE intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual occupational therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recruitment and retention
Number of subjects: 20
Study: 34116953

Group type: EXPERIMENTAL
Intervention: Biosynthetic resorbable parietal mesh (P4HB)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Biologic mesh
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 94
Study: 34117049

Group type: EXPERIMENTAL
Intervention: Vestibular assessment, motor assessment, neurocognitive tests, cognitive-motor interaction assessment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Vestibular dysfunction assessment
Number of subjects: 225
Study: 34117077

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34117380

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide implant (FAi)
Number of subjects: 87
Study: 34117510

Group type: EXPERIMENTAL
Intervention: Stress-induced hyperglycemic (SIH) group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hyperglycemia group (including SIH and DH)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Initial blood glucose level
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hyperglycemia group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: On-admission hyperglycemia
Number of subjects: 250
Study: 34117601

Group type: EXPERIMENTAL
Intervention: Home spirometry for IPF
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Site spirometry for IPF
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Home spirometry for non-IPF ILD
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Site spirometry for non-IPF ILD
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Physical functional capacity measured by daily home accelerometry for IPF
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) for IPF
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) for non-IPF ILD
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for IPF and non-IPF ILD
Number of subjects: 178
Study: 34117626

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 2214
Study: 34117638

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE) strain analysis
Number of subjects: 70
Study: 34117737

Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone (500 mg for 3 consecutive days, total of 1500 mg) followed by i.v. Tocilizumab (8 mg/kg) on day 3 and thereafter weekly s.c. Tocilizumab injections (162 mg) over 52 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucocorticoid pulse therapy
Number of subjects: 18
Study: 34117759

Group type: EXPERIMENTAL
Intervention: Increased X- and Y-chromosome dosage
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Correlation of X- and Y-chromosome-linked WMV changes
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: SCD-driven WMV changes
Number of subjects: 306
Study: 34118018

Group type: EXPERIMENTAL
Intervention: Transdermal 2% testosterone gel 300 mcg/day (T group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined therapy (T + E group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Local non-hormonal moisturizers (NH group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Local estrogens (E group)
Number of subjects: 81
Study: 34118197

Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once-daily oral treatment
Number of subjects: 233
Study: 34118198

Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once-daily oral treatment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 142
Study: 34118361

Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide via intraperitoneal injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide in oleic acid-induced HepG2 fatty liver cell model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AWRK6 synthetic peptide in insulin-induced HepG2 cells
Number of subjects: 0
Study: 34118396

Group type: EXPERIMENTAL
Intervention: mALPS-index
Number of subjects: 330
Study: 34118856

Group type: EXPERIMENTAL
Intervention: Care of the Dying Evaluation - Emergency Medicine questionnaire
Number of subjects: 30
Study: 34118909

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Young adults
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Individuals who studied
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Adolescents and young adults
Number of subjects: 476
Study: 34118944

Group type: EXPERIMENTAL
Intervention: Chloroquine (750 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no chloroquine)
Number of subjects: 14
Study: 34118981

Group type: EXPERIMENTAL
Intervention: Pen group (PG)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Syringe group (SG)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 34118986

Group type: EXPERIMENTAL
Intervention: Liraglutide (LRGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34119038

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34120214

Group type: EXPERIMENTAL
Intervention: Autologous antigen-specific T-cells (Melan-A and MELOE-1) with subcutaneous IL-2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Autologous antigen-specific T-cells (Melan-A and MELOE-1)
Number of subjects: 6
Study: 34120229

Group type: EXPERIMENTAL
Intervention: GRASP dynamic contrast-enhanced (DCE)-MRI
Number of subjects: 64
Study: 34120312

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg QD
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg QD
Number of subjects: 452

Group type: COMPARATOR
Intervention: PPI use
Number of subjects: 452
Study: 34120316

Group type: EXPERIMENTAL
Intervention: PNplus Panel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional microbiology
Number of subjects: 90
Study: 34120773

Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dasatinib 100 mg once daily
Number of subjects: 0
Study: 34122314

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study: 34122611

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34123791

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 0
Study: 34123956

Group type: EXPERIMENTAL
Intervention: National School-Based Health Lifestyles Intervention
Number of subjects: 0
Study: 34123963

Group type: EXPERIMENTAL
Intervention: Telehealth Delivered Rehabilitative Exercise (MSTEP)
Number of subjects: 0
Study: 34124106

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing treatment, specific intervention details not available
Number of subjects: 0
Study: 34124111

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Intravenous Analgesia with Tramadol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34124781

Group type: EXPERIMENTAL
Intervention: Nephrotoxic serum (NTS) administered on day 14 after EAV induction.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small molecule kinase inhibitor (fostamatinib) administered over a 4-day treatment period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control protein (not MPO) administered instead of MPO.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sub-nephritogenic NTS alone.
Number of subjects: 0
Study: 34124920

Group type: EXPERIMENTAL
Intervention: Top-down guidance with specific target template (picture cue)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Top-down guidance with semantic consistency (consistent vs. inconsistent)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bottom-up guidance with high salience targets
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Attentional capture by distractors (picture cue)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Attentional capture by distractors (all conditions)
Number of subjects: 2
Study: 34125075

Group type: COMPARATOR
Intervention: Best-practice condition (SMS notifications and survey)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile 360° videos (combined with best-practice condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivation and Problem Solving (MAPS) coaching (combined with best-practice condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile 360° videos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAPS coaching
Number of subjects: 0
Study: 34125405

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (8-week treatment)
Number of subjects: 2036
Study: 34125421

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 261
Study: 34125951

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1222
Study: 34125952

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus medical treatment
Number of subjects: 3793
Study: 34126109

Group type: EXPERIMENTAL
Intervention: ALXN1830 (10 mg/kg) administered as five weekly intravenous doses
Number of subjects: 8
Study: 34126262

Group type: EXPERIMENTAL
Intervention: PF-06480605 (500 mg intravenous every 2 weeks, 7 doses total)
Number of subjects: 50
Study: 34126278

Group type: EXPERIMENTAL
Intervention: Fluticasone, Azithromycin, and Montelukast (FAM) treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (non-BOS chronic GVHD, N=31)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no chronic GVHD, N=29)
Number of subjects: 33
Study: 34126756

Group type: EXPERIMENTAL
Intervention: Cardioprotective medications
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Normal myocardium (%) derived by fast-strain-encoded cardiovascular magnetic resonance
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 61
Study: 34126876

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34126939

Group type: EXPERIMENTAL
Intervention: TAF (25 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TDF (300 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ETV (0.5 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAF, TDF, ETV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 40
Study: 34126944

Group type: EXPERIMENTAL
Intervention: Cerebrovascular pathology
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Mixed pathology
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Neurodegeneration
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Pathological MRI markers (MTA and lacunes)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: History of clinical stroke prior to the index stroke
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PCI for women
Number of subjects: 410
Study: 34126949

Group type: EXPERIMENTAL
Intervention: Colon cancer surgery
Number of subjects: 0
Study: 34127247

Group type: EXPERIMENTAL
Intervention: Immediate improvement in left ventricular ejection fraction (LVEF) defined as an absolute increase of ≥5% in LVEF at post-procedure echocardiogram.
Number of subjects: 694

Group type: COMPARATOR
Intervention: No immediate improvement in left ventricular ejection fraction (LVEF).
Number of subjects: 694
Study: 34127618

Group type: EXPERIMENTAL
Intervention: Management strategies for post-PE syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation and treatment for chronic thromboembolic pulmonary hypertension (CTEPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active studies designed to optimize management of post-PE syndrome
Number of subjects: 0
Study: 34127633

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (1 h at 65% peak aerobic capacity)
Number of subjects: 15
Study: 34128387

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34128409

Group type: EXPERIMENTAL
Intervention: Serum Coll2-1
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Serum Coll2-1NO2
Number of subjects: 121
Study: 34128464

Group type: EXPERIMENTAL
Intervention: Primacy model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural encoding of the Primacy model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative temporal representations
Number of subjects: 0
Study: 34128558

Group type: EXPERIMENTAL
Intervention: ImmunoCAP™ sx1 and fx5 mixes
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ImmunoCAP ISAC™ 112 microarray
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Euroline™ panel
Number of subjects: 106

Group type: COMPARATOR
Intervention: All three assay systems
Number of subjects: 106
Study: 34128812

Group type: EXPERIMENTAL
Intervention: Motivation and Skills Support app, used for 8 weeks
Number of subjects: 31
Study: 34128818

Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens (web-based intervention)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 411
Study: 34128819

Group type: EXPERIMENTAL
Intervention: e-mhGAP-IG training
Number of subjects: 35

Group type: COMPARATOR
Intervention: mhGAP-IG v2.0 training (control)
Number of subjects: 35
Study: 34128911

Group type: EXPERIMENTAL
Intervention: Oxford-12 Hip Score
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: HOOS-12
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Equipercentile method
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mapping methods (linear regression, tobit regression, quantile regression)
Number of subjects: 500
Study: 34129158

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem/stromal cells (ADSC) infusion at a dosage of 1 million cells/kg of body weight via intravenous route.
Number of subjects: 31